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DEN-induced Ras membrane activity and induces apoptosis
in transformed hepatocytes as indicated by high liver
caspase 3 activity and an increased number of Tunel positive
cells in GSTp-expressing hepatocytes. Apoptosis induction is
associated with up-regulation of Fas, Fas ligand and JNK
phosphosphorylation that occurs independently of TNFa and
Trail. Bax, Bcl2, Bcl-xl expression and cytochrome C release
is not affected by FTS.
Conclusions: FTS inhibits Ras activation in the liver
and prevents preneoplastic liver nodule development by
inducing apoptosis in transformed hepatocytes. FTS-induced
apoptosis is related to activation of the extrinsic pathway
involving the Fas/Fas ligand system. Therefore, FTS might
be a promising agent for the development of new
therapeutic strategies in HCC.
I-4 Blood sugar test: non-invasive diagnosis for liver
diseases
C. Chen*. Department of Molecular Biology, Ghent
University and Department for Molecular Biomedical
Research, VIB, Gent, Belgium
Hepatocellular carcinoma (HCC), also known as primary
liver cancer, is the ﬁfth most common cancer worldwide. No
completely accurate screening test for liver cancer exists.
Doctors sometimes use a blood test that checks for the
presence of alpha-fetoprotein (AFP) a type of protein not
normally found in adults to screen people at high risk of
the disease.
Unfortunately, an elevated level of AFP is detectable in
only about two-thirds of patients with early-stage HCC,
and high mortality from HCC is due to the inability to
detect these cancers in their earliest stages. Thus, to detect
small tumors, a very sensitive biomarker is needed, with
an intensity that should be proportional to the size of the
tumor.
Protein glycosylation, the most common form of co-
translational modiﬁcation of proteins, is the enzymatic
addition of sugars or oligosaccharides (or glycans) to
proteins. Protein glycosylation increases the diversity of
the functions of proteins encoded in the genome. The result
is that different glycomes of the same protein may have
different functional, kinetic or physical properties. Because
the condition of the cells largely regulates glycosylation
pathway, the type of glycan produced by cells, tissue, or
organism could reﬂect their current physiological state.
This means that the sugar chains can be altered by the
physiological or pathophysiological condition of the cell.
Our group took advantage of a recently developed technique
to study the total glycome (N-linked sugars) pattern of
protein mixtures, e.g. serum proteins. Sugar trees are cut
from the proteins, collected and separated. We have been
able to analyze the serum samples of over 500 cirrhosis
patients. It was clear that the changes in serum glycome
correlated with the presence of tumors and with tumor
size. This study included 450 HBV-infected patients with
liver ﬁbrosis, cirrhosis and HCC. We found that a branch
alpha(1,3)-fucosylated triantennary glycan (NA3Fb) was
more abundant in HCC patients than in cirrhosis patients,
ﬁbrosis patients and healthy blood donors, whereas a
bisecting core alpha (1,6)-fucosylated biantennary glycan
(NA2FB) was elevated in cirrhosis patients. The ratio of
these values forms the basis of the new blood test (the
log ratio of peak9/peak7, renamed as GlycoHCCTest). Using
GlycoHCCTest, we were able to make the correct diagnosis
in 70% of the cases, a success rate that equals that of the
AFP tumor marker currently used in the clinic. Promisingly,
when the AFP test was used in combination with the new
GlycoHCCTest, the accuracy of HCC diagnosis increased
dramatically. The new glycomic test succeeded in detecting
the liver cancer in more than half of the patients with
cirrhosis and cancer of the liver for whom the AFP test was
inconclusive.
I-5 HBV genome oncogenic mutations in Chinese HCC
patients related to chronic HBV infection
F.M. Lu*, S.Z. Jiang, X.M. Chen, H. Zhuang. Department
of Microbiology, Peking University Health Science Center,
Beijing, 100191, China
Aims: To identify the HBV oncogenic mutations associated
to the Chinese patients with HCC.
Method: For mutation screening, HBV preS/S gene, X gene
and precore region were ampliﬁed from liver tumor and
their matched paratumor tissue by PCR and analyzed by
direct sequencing. Cassette ligation mediated PCR was used
to analyze HBx integration mutation.
Results: HBV mutation was analyzed in 41 tumor tissues
and 33 non-tumor tissues (among them 32 were paired).
Phylogenetic analysis revealed that 87.3% strains were
genotype C, 8% genotype B, 1.6% genotype D, 3.1%
genotype A. From these samples, pre-S/S gene and X gene
and precore regions from 110 sequences were analyzed
separately. X gene’s carboxyl-terminal deletion (from 6 to
114 amino acids) was found in 20/38 (52.6%) of tumor
samples and only in 9/30 (30%) of paratumor samples.
Concordant to our previous work, pre-S1 start codon in-
frame deletion, pre-S2 start codon mutation and pre-S2
in-frame deletion were all detected in both tumor tissue
and paratumor tissues tested, with a higher tendency
in tumor samples. Interestingly, pre-S1 deletion involving
the S promoter was found in 5 tumor tissue while none
in the paired paratumor tissues, indicating the tumor
associated mutation. However, it is noteworthy that a
higher T1762/A1764 mutation and precore A1896 mutation
frequencies were found in our study: T1762/A1764 mutation
or deletion in 31/41 (75.6%) of tumor samples and in
26/30 (86.7%) paratumor samples; the A1896 mutation
or deletion in 24/37 (64.9%) tumor samples and in
19/28(67.9%) paratumor sample, though there was no
signiﬁcant difference. HBx integration was detected in 7/32
HCC samples and only in 1/22 paratumor samples (among
them 19 were paired). In 2 tumor samples, 2 different
HBx integration sites were found. Ten of 11 integration
events resulted in HBx C-terminal truncated mutations,
except 1 interstitial deletion within the HBx gene in a
tumor sample. Interestingly, though the integration sites in
human genome was random, 5 of 11 breaking sites (4 in the
tumor and 1 in the paratumor sample) were within the DR1
sequence.
Conclusion: Pre-S1 deletion involved S promoter sequence
was only demonstrated in tumor tissues and indicated such
mutation was probably oncogenic; HBx carboxyl-terminal
deletion were more common in tumor than in paratumor
tissues tested, implicating a role in liver carcinogenesis.
In contrast to several previous reports, high frequency
mutations involving pre-S2 gene, X gene, BCP, T1762/A1764
and pre-C A1896 were found in both tumor and paratumor
tissues with no signiﬁcant difference. It is suggested that
such mutations were simply as a result of accumulation with
time of persistent infection and not oncogenic.
I-6 Risks and results of the living related liver
transplantation in Europe
B. de Hemptinne*. Department of Surgery, University
Hospital of Ghent, Belgium
The European Liver Transplantation registree (ELTR) has
cumulated data concerning 54,133 cadaveric full-size
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liver transplants and the 2,043 living related liver
transplantations.
The analysis of the living donor liver transplantations is
done with special focus on recipient selection, type of
indications, outcome and risk of procedure between 1991
and June 2006.
Methods: 54% of European transplant centers have voluntary
participated to the ELTR of living donor transplantation; 34%
of living transplants are done in children and 3% in adults.
Audit visits are performed to assess the quality of the data.
Results: The donors of the living related transplantations
are younger (35±10 years vs 41±18 years, p < 0.01) and
more females have been donors compared to the full-size
transplanted group (50% livings vs 40% full-size). There are
no differences in the age of the adults but the children
transplanted with a living donor are younger. The 8 year
survival of all transplanted grafts from livings is superior
than the one of the full-size grafts (63% vs 54%) mainly
due to the excellent results in children. The results are
equivalent in the adult population with the living donors
as with the full-size whether the indication is cirrosis or
HCC. This is despite the fact that the selection of patients
suffering from HCC could have been more liberal in the
living transplanted group. Living transplantation for HCC
is proportionally also more frequent than in the full-size
group.
When analysing the type of graft used, we ﬁnd that in
91% of adults the right liver was chosen. The majority (85%)
of the children got the left lobe; 12% were transplanted
with left livers and 3% with right livers. The overall survival
was not inﬂuenced by the choice of liver size in children
when differences in survival according to graft volume and
type of grafts where highly signiﬁcant in adults.
The study of the donors shows as expected that the more
liver resected, the more transient hyper bilirubinemia and
liver insufﬁciency but also more biliary complications. Four
donors (0.2%) died; 2 of sepsis and multiple organ failure,
1 of pulmonar embolism and 1 of heart failure.
The main cause of recipient death in the adult transplanted
population is graft failure, related to technical problems
with the vascular anastomosis or insufﬁcient graft volume.
The preventive measures to palliate these problems were
mainly the ligature of the splenic artery and selective
portocaval shunt.
In conclusion: The use of living related liver transplantation
is increasing but still marginal in adult population. The
donor mortality risk is lower than initially estimated but
the donor complication rate remains high. Despite the fact
that HCC is the main indication in adults, the results of the
transplantation are equivalent to those recorded with the
full-size grafts. Technical problems remain frequent mostly
in low volume centers.
I-7 Shear stress: a trigger for liver regeneration
cascade?
Y.D. Fan*. Department of Surgery, Ghent University
Hospital, Ghent, Belgium
The liver has a unique capacity to regenerate, which allows
it to recover from parenchymal loss or damage without
jeopardizing its vital functions. Amongst the remaining puz-
zles of the complex mechanisms of liver regeneration, what
ﬁrst triggers the regeneration cascade is still debatable.
Shear stress after partial hepatectomy is suggested as a
possible initiator. As the other factors generated by surgical
trauma may also be inﬂuential, we tested this hypothesis
in a novel rat model, in which shear stress was increased
without affecting liver volume and function.
An increase of portal venous pressure, reﬂecting shear
stress, was realised by portal vein arterialisation.
Liver damage was assessed by serum biochemistry and
morphology (light and electron microscopy). Hepatic
proliferating activity was evaluated by proliferating cell
marker Ki-67, mitosis and liver weight. Messenger RNA
expression of endothelial nitric oxide synthase (eNOS) and
immediate early gene c-fos was determined by Q-PCR.
After surgery, portal venous pressure increased to a
level comparable to that of after a standard 2/3 partial
hepatectomy. Despite a transient moderate elevation of
serum aminotransferase, neither parenchymal nor sinusoidal
endothelium damages were identiﬁed by morphology. Forty-
eight hours later, the number of Ki-67+ hepatocytes
was drastically increased, which was accompanied with
numerous mitoses of hepatocytes. Compared with the
control animals, liver weight was also higher in the rats
with high portal pressure. mRNA expression of eNOS and
c-fos was upregulated instantly after portal reperfusion. In
addition, the mRNA expression of both eNOS and c-fos was
correlated to portal pressure.
These data demonstrate that an increased shear stress alone
can initiate hepatic proliferation even without mass loss or
profound injury of the liver. The nitric oxide-c-fos pathway
may be involved in this initiating process.
I-8 Contrast enhanced magnetic resonance imaging
as virtual biopsy for diagnosis and therapeutic
assessment of liver malignancies
Y. Ni *. Section of Radiology, Department of Medical
Diagnostic Sciences, Biomedical Sciences Group, University
of Leuven, Belgium
Driven by the increasing demands for improved
sensitivity and speciﬁcity in diagnosis of focal hepatic
lesions with magnetic resonance imaging (MRI), a few
hepatobiliary contrast agents (CAs) such as gadolinium
ethoxybenzyl diethylenetriaminopentacetic acid (Gd-EOB-
DTPA, Primovist®), Gadobenate dimeglumine (Gd-BOPTA,
Multihance®), and manganese dipyridoxal-diphosphate (Mn-
DPDP, Teslascan®) have been successfully developed and
applied in clinical patients. Being hepatotropic, these
CAs undergo intracellular uptake and biliary excretion
through certain metabolic pathways, hence well ﬁtting
the current molecular MRI concept. Although they were
originally designed for improving liver lesion detection,
these CAs have been explored during preclinical studies
for noninvasive characterization of histopathological nature
of focal hepatic lesions, i.e. using contrast enhanced
MRI as virtual biopsy. This is realized by exploiting the
difference in uptake and excretion dynamics between
normal liver and neoplastic lesions of different histological
origins and metabolic functions. These CAs were evaluated
by using rodent liver tumor models, and the meticulous
imaging-histology colocalization methodology guaranteed
study reliability. In summary, liver tumors of different origins
and grades of cellular differentiation can be detected and
classiﬁed according to their contrast enhancement patterns
occurring at certain postcontrast phases. The degree or
tendency in invasiveness of liver malignant tumors can be
also implicated by the presence or absence of peritumoral
rim signs. Such diagnostic information, otherwise impossible
or only achievable invasively, may prove invaluable for
decision-making in oncological healthcare. Despite early
objections, our preclinical ﬁndings have been conﬁrmed by
later clinical outcomes when these hepatobiliary CAs are
widely used in human patients.
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